Literature DB >> 7489803

Fibrinolytic and inflammatory processes in pleural effusions.

F Philip-Joët1, M C Alessi, C Philip-Joët, M Aillaud, J R Barriere, A Arnaud, I Juhan-Vague.   

Abstract

This study was designed to evaluate major fibrinolytic parameters in relation to parameters of inflammation associated with different kinds of pleural effusion. Sixty patients with pleural effusion were studied. The underlying aetiology was empyema in 10 cases, tuberculosis in 9, cancer in 31, cardiac failure in 7, and undetermined in 3. Plasminogen, plasminogen activator inhibitor 1 (PAI-1) and 2 (PAI-2), tissue type plasminogen activator (t-PA), urokinase (u-PA) and D-dimers (D-D) were quantified in plasma samples and pleural effusion specimens. These data were then correlated with inflammatory or infectious parameters, i.e. fibrinogen, von Willebrand factor (vWF), erythrocyte sedimentation rate (ESR), protein concentration, and white blood cell count. D-D levels were higher in pleural fluid than in plasma. D-D levels were not correlated with either plasminogen activator or plasminogen activator inhibitor levels, suggesting the presence of other fibrinolytic pathways. PAI levels (PAI activity, PAI-1 antigenicity, PAI-2 antigenicity) and vWF levels were significantly higher in patients with tuberculosis and empyema than in patients with cancer or cardiac failure. Regression analysis between inflammatory and fibrinolytic parameters showed that pleural PAI levels were significantly correlated with pleural neutrophil count, vWF levels, and plasma fibrinogen levels. D-D levels were correlated with blood ESR. No significant difference in pleural t-PA, u-PA and D-D levels was observed between aetiologies. The highest pleural t-PA and u-PA values were noted in patients with cancer, especially lymphoma. Plasma t-PA levels were higher inpatients with pleural effusion secondary to congestive heart failure, but this difference did not reach statistical significance.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489803     DOI: 10.1183/09031936.95.08081352

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  29 in total

1.  Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids.

Authors:  Andrey A Komissarov; Galina Florova; Ali Azghani; Sophia Karandashova; Anna K Kurdowska; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-08-30       Impact factor: 5.464

Review 2.  Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection.

Authors:  Francesco Piccolo; Natalia Popowicz; Donny Wong; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 3.  Pneumococcal microbial surface components recognizing adhesive matrix molecules targeting of the extracellular matrix.

Authors:  Gavin K Paterson; Carlos J Orihuela
Journal:  Mol Microbiol       Date:  2010-04-27       Impact factor: 3.501

4.  Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali Azghani; Sophia Karandashova; Chris Schaefer; Kathleen Koenig; Kris Stewart-Evans; Paul J Declerck; Steven Idell; Andrey A Komissarov
Journal:  Am J Respir Cell Mol Biol       Date:  2015-04       Impact factor: 6.914

5.  Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study.

Authors:  Carmen Alemán; José M Porcel; José Alegre; Eva Ruiz; Silvia Bielsa; Jordi Andreu; Maria Deu; Pilar Suñé; Mireia Martínez-Sogués; Iker López; Esther Pallisa; Joan Antoni Schoenenberger; J Bruno Montoro; Tomás Fernández de Sevilla
Journal:  Lung       Date:  2015-09-30       Impact factor: 2.584

6.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

7.  Plasmin enhances cell surface tissue factor activity in mesothelial and endothelial cells.

Authors:  H Kothari; G Kaur; S Sahoo; S Idell; L V M Rao; U Pendurthi
Journal:  J Thromb Haemost       Date:  2008-11-03       Impact factor: 5.824

8.  Does plasminogen activator inhibitor-1 drive lymphangiogenesis?

Authors:  Françoise Bruyère; Laurence Melen-Lamalle; Silvia Blacher; Benoît Detry; Anne Masset; Julie Lecomte; Vincent Lambert; Catherine Maillard; Gunilla Høyer-Hansen; Leif R Lund; Jean-Michel Foidart; Agnès Noël
Journal:  PLoS One       Date:  2010-03-11       Impact factor: 3.240

9.  Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacerbates tetracycline-induced pleural injury in rabbits.

Authors:  Sophia Karandashova; Galina Florova; Ali O Azghani; Andrey A Komissarov; Kathy Koenig; Torry A Tucker; Timothy C Allen; Kris Stewart; Amy Tvinnereim; Steven Idell
Journal:  Am J Respir Cell Mol Biol       Date:  2012-09-20       Impact factor: 6.914

10.  Profile of Metalloproteinases and Their Association with Inflammatory Markers in Pleural Effusions.

Authors:  Lisete Ribeiro Teixeira; Murilo B Dias; Roberta K B Sales; Leila Antonangelo; Vanessa A Alvarenga; Juliana Puka; Evaldo Marchi; Milena Marques Pagliarelli Acencio
Journal:  Lung       Date:  2016-09-27       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.